Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 16

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 16
---
3a) and higher reduction of bacterial load (by 99.5% against the control group) in the non-lethal MRSA bacteraemia rat model (Figure 3b).

<div align='center'>S-7</div>

Figure 3a

Figure 3a: Oral Formulation
of ALS-4 in an MRSA Survival Study

Figure 3b

Figure 3b: Oral Formulation
of ALS-4 in a Non-Lethal Bacteremia Model

CFU = Colony Forming Unit, a unit used
to estimate the number of viable bacteria in a sample

A Clinical Trial Application
(“CTA”) was submitted with the Public Health Agency of Canada (Health Canada) to conduct a Phase 1 clinical trial of
ALS-4, an orally administered small molecule drug for the treatment of infections caused by Staphylococcus aureus including Methicillin-resistant
Staphylococcus aureus (MRSA) in Q4 2020. ALS-4 received clearance from Health Canada regarding the CTA to initiate a Phase 1 clinical
study in January 2021. In March 2021, we announced dosing the first human subject in its Phase 1 clinical trial evaluating
ALS-4. In January 2022, we further announced the completion of our Phase I clinical trial for ALS-4. The first-in-human Phase 1
trial was a randomized, double-blinded, placebo-controlled, single, and multiple ascending dose study designed to evaluate safety, tolerability,
and pharmacokinetics of orally administered ALS-4 in healthy male and female adult volunteers. The single-ascending dose studies (SAD)
and multiple-ascending dose studies (MAD) have been completed for a total of 72 healthy subjects and no subjects were dropped from the
studies. There were no serious adverse events observed and no relevant clinical changes in respect of vital signs. In March 2023,
we announced the completion of the Pre-IND discussions with the US FDA. The Pre-IND discussions focused on overall development plan
in preparation for the IND application of ALS-4 targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI) initially.

<div align='center'>S-8</div>

With the positive feedback
on the overall development strategy from the US FDA, we are proceeding towards the IND submission of ALS-4 seeking to initiate a Phase 2
clinical study to assess the efficacy of ALS-